Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRENCH: Sevelamer Carbonate in CKD Patients Not on Dialysis
NCT01220843Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2010
- Primary completion
- Apr 2013
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Placebo with Sevelamer carbonate (2 arms). Primary endpoint: Serum levels of C terminal segment of fibroblast growth factor 23 at 12 weeks. Started Oct 2010; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01220843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220843.